<p>Note 1: the pamidronate regime consisting of the intravenous administration of 90 mg pamidronate every 4 weeks for a period of 2 years is used as a base.</p
Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate th...
We present three clinical cases of successful osteoporosis treatment with denosumab in patients with...
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
<p>(a) The active osteoclast using the identified denosumab regimes. (b) The bone volume using the i...
<p>Evaluations of the calibration and validation of pharmacokinetic models of pamidronate and denosu...
Denosumab is a very effective treatment of osteoporosis, easy to use and very well tolerated. Due to...
<p>The clinical datasets used for the calibration and validation of the integrated models with pamid...
<p>Note 1: The r<sup>2</sup> is calculated before 30 days after pamidronate treatment.</p><p>Note 2:...
<p>(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmaco...
Robert A Adler, Ranjodh S GillEndocrinology and Metabolism, McGuire Veterans Affairs Medical Center,...
Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It le...
Source Data with BMD and lab result data - contact authors for further informatio
Purpose: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus t...
This randomized study compared denosumab, a fully human monoclonal antibody against receptor activat...
Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate th...
We present three clinical cases of successful osteoporosis treatment with denosumab in patients with...
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
<p>(a) The active osteoclast using the identified denosumab regimes. (b) The bone volume using the i...
<p>Evaluations of the calibration and validation of pharmacokinetic models of pamidronate and denosu...
Denosumab is a very effective treatment of osteoporosis, easy to use and very well tolerated. Due to...
<p>The clinical datasets used for the calibration and validation of the integrated models with pamid...
<p>Note 1: The r<sup>2</sup> is calculated before 30 days after pamidronate treatment.</p><p>Note 2:...
<p>(a) The calibration of the pharmacokinetic model of denosumab. (b) The validation of the pharmaco...
Robert A Adler, Ranjodh S GillEndocrinology and Metabolism, McGuire Veterans Affairs Medical Center,...
Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It le...
Source Data with BMD and lab result data - contact authors for further informatio
Purpose: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus t...
This randomized study compared denosumab, a fully human monoclonal antibody against receptor activat...
Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate th...
We present three clinical cases of successful osteoporosis treatment with denosumab in patients with...
<p>The calibrated parameter values of the integrated models with pamidronate and denosumab.</p
DOI
Add to ORKG